Methods and Systems for Analyzing Nucleic Acid Molecules

Smart overview of the Invention

The patent application outlines innovative methods and systems for analyzing nucleic acid molecules to detect conditions like cancer, transplant rejection, and fetal genetic abnormalities. By sequencing cell-free nucleic acids from a subject, the technology can identify genetic sequences indicative of these conditions. This approach enhances the sensitivity and specificity of diagnostic tests, offering a noninvasive way to monitor and potentially guide clinical interventions.

Technical Approach

The process involves obtaining sequencing data from cell-free nucleic acids, such as cfDNA and cfRNA, and using a computer system to identify phased variants in the genetic sequence. The presence of these variants, which are separated by at least one nucleotide, can suggest the presence of a condition. The method also includes identifying insertions and deletions (indels) to refine the diagnosis further and assess the subject's condition.

Applications and Benefits

By improving the detection limits to less than 1 in 50,000 observations, the method allows for more accurate identification of minimal residual disease (MRD) in cancer patients. This capability is particularly crucial for diseases where current detection methods yield false negatives, such as diffuse large B-cell lymphoma. The technology's enhanced detection capabilities can lead to better prognostic evaluations and treatment decisions.

Implementation and Techniques

The sequencing data can be generated through various methods, including next-generation sequencing (NGS) and polymerase chain reaction (PCR), without relying on molecular or sample barcoding. This flexibility in data generation methods allows for broad application across different diagnostic platforms. The use of in silico techniques to manage background and sequencing errors is minimized, focusing on the accuracy of the sequencing itself.

Clinical Impact

The methods described not only aid in diagnosing conditions but also in monitoring disease progression and treatment effectiveness. By comparing sequencing data over time, clinicians can assess changes in the subject's condition, allowing for timely adjustments in treatment strategies. The government-supported research underscores the potential impact of this technology on public health, particularly in improving early detection and treatment outcomes for serious medical conditions.